In another blow to big pharma, India's Supreme Court rejects Novartis's Glivec patent plea
India’s Supreme Court has issued its eagerly anticipated judgment in the long-running Glivec patent case. Upholding previous decisions, the court ruled that the country’s patent office was right to refuse a patent to Novartis for its anti-cancer…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.